Human albumin: Old, new, and emerging applications

Annals of Transplantation

Volumn 18, Issue 1, 2013, Pages 205-217

  Rozga, Jacek ^a   Piatek, Tomasz ^a   Małkowski, Piotr ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Albumin; Albumin binding capacity; Albumin supplementation; Blood detoxification; Fluid resuscitation; Hypoalbuminaemia; Liver failure

Indexed keywords

ALBUMIN; DIURETIC AGENT; HUMAN ALBUMIN; HUMAN SERUM ALBUMIN;

ANTIOXIDANT ACTIVITY; ASCITES; BACTERIAL PERITONITIS; CRITICALLY ILL PATIENT; HEMOFILTRATION; HEPATORENAL SYNDROME; HUMAN; HYPOALBUMINEMIA; LIVER FAILURE; LIVER SUPPORT; PARACENTESIS; PATHOPHYSIOLOGY; REVIEW;

EID: 84887244925     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.889188     Document Type: Review

References (100)

1. Janeway CA, Gibson ST, Woodruff LM et al: Chemical, clinical and immunological studies on the products of human plasma fractionation: concentrated human serum albumin. J Clin Invest, 1944; 23: 465-91
2. Finfer S, Bellomo R, Boyce N et al: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med, 2004; 350: 2247-56
3. Vincent J-L: Relevance of albumin in modern critical care medicine. Best Pract Res Clin Anaesth, 2009; 23: 183-91
4. Garcovich M, Zocco MA, Gasbarrini A: Clinical use of albumin in hepatology. Blood Transfus, 2009; 7: 268-77
5. Cochrane Injuries Group: Human albumin administration in critically ill patients: systematic review of randomized controlled trials. BMJ (Clinical Research Ed.), 1998; 317: 235-40
6. McClelland B: Albumin: don't confuse us with the facts. Br Med J, 1998; 317: 829-30
7. Wilkes M, Navickis RJ: Patient survival after albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med, 2001; 135: 149-64
8. Vincent JL, Wilkes MM, Navickis RJ: Safety of human albumin: serious adverse events reported worldwide in1998-2000. Br J Anaesth, 2003; 91: 625-30
9. Vincent JL, Sakr Y, Reinhart K et al: Is albumin administration in the acutely ill associated with increased mortality? Results of the SOAP study. Critical Care (London, England), 2005; 9: R745-54
10. Sort P, Navasa M, Arroyo V et al: Effects of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med, 1999; 342: 403-9
11. Fernandez J, Monteagudo J, Bargallo X et al: Randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology, 2005; 42: 627-34
12. Ortega R, Gines P, Uriz J et al: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology, 2002; 36: 941-48
13. Salerno F, Gerbes A, Gines P et al: Diagnosis, prevention and treatment of the hepatorenal syndrome in cirrhosis. Gut, 2007; 56: 1310-18
14. Sugio S, Kashima A, Mochizuki S et al: Crystal structure of human serum albumin at 2.5 A resolution. Protein Eng, 1999; 12(6): 439-46
15. Peters TJ: The albumin molecule: its structure and chemical properties. In: All About Albumin. Biochemistry, Genetics And Medical Applications. San Diego: Academic Press, 1996; 9-75
16. Beeken WL, Volwiler W, Goldsworthy PD et al: Studies of I-131-albumin catabolism and distribution in normal young male adults. J Clin Invest, 1962; 41: 1312-33
17. Schnitzer, JE, Oh P: Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins. J Biol Chem, 1994; 269(8): 6072-82
18. Carter DC, He XM: Structure of human serum albumin. Science. 1990; 249(4966): 302-3
19. Carter DC, Ho JX: Structure of serum albumin. Adv Protein Chem, 1994; 45: 153-203
20. He XM, Carter DC: Atomic structure and chemistry of human serum albumin. Nature, 1992; 358: 209-15
21. Nicholson JP, Wolmarans MR, Park GR: The role of albumin in critical illness. Br J Anaesth, 2000; 85: 599-610
22. th ed. Connecticut: Appleton and Lange, 1995; 525-41
23. McAuliffe JJ, Lind LJ, Leith DE, Fencl V: Hypoproteinemic alkalosis. Am J Med, 1986; 81: 86-90
24. Doweiko JP, Nompleggi DJ: Role of albumin in human physiology and pathophysiology. J Parent Ent Nutr, 1991; 15: 207-11
25. Holt ME, Ryall MET, Campbell AK: Albumin inhibits human polymorphonuclear leucocyte luminol dependent chemiluminescence: evidence for oxygen radical scavenging. Br J Exp Pathol, 1984; 65: 231-41
26. Roche M, Rondeau P, Singh NR et al: The antioxidant properties of serum albumin. FEBS Letters, 2008; 582: 1783-87
27. Kouoh F, Gressier B, Luyckx M et al: Antioxidant properties of albumin: effect on oxidative metabolism of human neutrophil granulocytes. Farmaco, 1999; 54: 695-99
28. Wratten ML, Sereni L, Tetta C: Oxidation of albumin is enhanced in the presence of uremic toxins. Renal Failure, 2001; 23: 563-71
29. Ogasawara Y, Isoda S, Tanabe S: Antioxidant effects of albumin-bound sulfur in lipid peroxidation of rat liver microsomes. Biol Pharm Bull, 1999; 22: 441-45
30. Zoellner H, Hofler M, Beckmann R et al: Serum albumin is a specific inhibitor of apoptosis in human endothelial cells. J Cell Sc, 1996; 109: 2571-80
31. Fleck A, Raines G, Hawker F et al: Increased vascular permeability: a major cause of hypoalbuminemia in disease and injury. Lancet, 1985; 1: 781-83
32. Demling RH: Effect of plasma and interstitial protein content on tissue oedema formation. Curr Stud Hematol Blood Transf, 1986; 53: 36-52
33. Joorgensen KA, Stoffersen E: Heparin like activity of albumin. Thromb Res, 1979; 16: 569-74
34. Grigoriadis G, Stewart AG: Albumin inhibits platelet-activating factor (PAF)-induced responses in platelets and macro-phages: implications for the biologically active form of PAF. Br J Pharmacol, 1992; 107: 73-77
35. Jorgensen KA, Stoffersen E: On the inhibitory effect of albumin on platelet aggregation. Thromb Res, 1980; 17: 13-18
36. Moshage HJ, Janssen JA, Franssen JH et al: Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest, 1987; 79: 1635-41
37. Brenner DA, Buck M, Feitelberg SP, Chojkier M: Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia. J Clin Invest, 1990; 85: 248-55
38. Mansoor O, Cayol M, Gachon P et al: Albumin and fibrinogen syntheses increase while muscle protein synthesis decreases in head-injured patients. Am J Physiol Endocrinol Metab, 1997; 273: E898-902
39. Fritz HG, Brandes H, Bredle DL et al: Post-operative hypoalbuminaemia and procalcitonin elevation for prediction of outcome in cardiopulmonary bypass surgery. Acta Anaesth Scand, 2003; 47: 1276-83
40. Herrmann FR, Safran C, Levkoff SE, Minaker KL: Serum albumin level on admission as a predictor of death, length of stay, and readmission. Arch Int Med, 1992; 152: 125-30
41. McCluskey A, Thomas AN, Bowles BJ, Kishen R: The prognostic value of serial measurements of serum albumin concentration in patients admitted to an intensive care unit. Anaesthesia, 1996; 51: 724-27
42. Finfer S, Bellomo R, McEvoy M et al: Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: analysis of data from the Saline versus Albumin Fluid Evaluation (SAFE) Study. BMJ (Clinical Research Ed.), 2006; 333: 1044
43. Ryan AM, Hearty A, Prichard RS et al: Association of hypoalbuminemia on the first postoperative day and complications following esophagectomy. J Gastrointest Surg, 2007; 11: 1355-60
44. Schirmer-Mikalsen K, Vik A, Gisvold SE et al: Severe head injury: control of physiological variables, organ failure and complications in the intensive care unit. Acta Anaesth Scand, 2007; 51: 1194-201
45. Tung CF, Chow WK, Chang CS et al: The prevalence and significance of hypoalbuminemia in non-variceal upper gastrointestinal bleeding. Hepatogastroenterology, 2007; 54: 1153-56
46. Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC: Albumin levels predict survival in patients with systolic heart failure. Am Heart J, 2008; 155: 883-89
47. Foley EF, Borlase BC, Dzik WH et al: Albumin supplementation in the critically ill: a prospective randomised trial. Arch Surg, 1990; 125: 739-42
48. Stockwell MA, Scott A, Day A et al: Colloid solutions in the critically ill. A randomised comparison of albumin and polygeline. 2. Serum albumin concentration and the incidences of pulmonary oedema and acute renal failure. Anaesthesia, 1992; 47: 7-9
49. Vincent JL, Dubois MJ, Navickis RJ, Wilkes MM: Hypoalbuminemia in acute illness: is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Ann Surg, 2003; 237: 319-34
50. Friedman G, Jankowski S, Shahla M et al: Hemodynamic effects of 6% and 10% hydroxyethyl starch solutions versus 4% albumin solution in septic patients. J Clin Anesth, 2008; 20: 528-33
51. van der Heijden M, Verheij J, van Nieuw Amerongen GP, Groeneveld AB: Crystalloid or colloid fluid loading and pulmonary permeability, edema, and injury in septic and nonseptic critically ill patients with hypovolemia. Crit Care Med, 2009; 37: 1275-81
52. th 1995. Ann Fr Anesth Reanim, 1996; 15: 1124-29
53. Myburgh J, Cooper J, Finfer S et al: Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med, 2007; 357: 874-84
54. Liumbruno G, Bennardello F, Lattanzio A et al., as Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Working Party: Recommendations for the use of albumin and immunoglobulins. Blood Transf, 2009; 7: 216-34
55. Johnson PN, Romanelli F, Smith KM et al: Analysis of morbidity in liver transplant recipients following human albumin supplementation: a retrospective pilot study. Progr Transplant, 2006; 16: 197-205
56. Mukhtar A, El Masry A, Moniem AA et al: The impact of maintaining normal serum albumin level following living related liver transplantation: Does serum albumin level affect the course? A pilot study. Transplant Proc, 2007; 39: 3214-18
57. Rice JP, Skagen C, Said A: Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin. Transplantation, 2011; 91: 1131-47
58. Boyer TD, Sanyal AJ, Garcia-Tsao G et al: Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl, 2011; 17: 1328-32
59. Goldwasser P, Feldman J: Association of serum albumin and mortality risk. J Clin Epidemiol, 1997; 50: 693-703
60. Kaysen GA, Johansen KL, Cheng SC et al: Trends and outcomes associated with serum albumin concentration among incident dialysis patients in the United States. J Renal Nutr, 2008; 18: 323-31
61. Sullivan DH, Roberson PK, Bopp MM: Hypoalbuminemia 3 months after hospital discharge: significance for long-term survival. J Amer Geriat Soc, 2005; 53: 1222-26
62. Vincent JL, Navickis RJ, Wilkes MM: Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials. Crit Care Med, 2004; 32: 2029-38
63. Myburgh JA, Finfer S: Albumin is a blood product too-is it safe for all patients? Crit Care Resusc, 2009; 11: 67-70
64. Martin GS, Moss M, Wheeler AP et al: A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med, 2005; 33: 1681-87
65. Dubois MJ, Orellana-Jimenez C, Melot C et al: Albumin administration improves organ function in critically ill hypoalbuminemic patients: a prospective, randomized, controlled, pilot study. Crit Care Med, 2006; 34: 2536-40
66. Gentilini P, Casini-Raggi V, Di Fiore G et al: Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol, 1999; 30: 639-45
67. Trotter J, Pieramici E, Everson GT: Chronic albumin infusions to achieve diuresis in patients with ascites who are not candidates for transjugular intrahepatic portosystemic shunt (TIPS). Dig Dis Sci, 2005; 50: 1356-60
68. Gines A, Fernandez-Esparrach G, Monescillo A et al: Randomised trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology, 1996; 111: 1002-10
69. Moore KP, Wong F, Gines P et al: The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology, 2003; 38: 258-66
70. Boldt J: Use of albumin: an update. Br J Anesth, 2010; 104(3): 276-84
71. Runyon BA: Albumin infusion for spontaneous bacterial peritonitis. Lancet, 1999; 354: 1838-39
72. Rimola A, Garcia-Tsao G, Navasa M et al: Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol, 2000; 32: 142-53
73. Skagen C, Einstein M, Lucey MR, Said A: Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol, 2009; 43: 680-85
74. Tamion F: Albumin in sepsis. Ann Fr Anesth Reanim, 2010; 29: 629-34
75. Dellinger RP, Levy MM, Carlet JM et al., International Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med, 2008; 36: 296-327
76. Haller C: Hypoalbuminemia in renal failure: pathogenesis and therapeutic considerations. Kidney Blood Press Res, 2005; 28: 307-10
77. Stange J, Ramlow W, Mitzner S et al: Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs, 1993; 17: 809-13
78. Falkenhagen D, Strobl W, Vogt G et al: Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs, 1999; 23: 81-86
79. Rozga J: Selective Plasma Exchange Therapy. Patent CA 2495459. Priority date 2003-08-11
80. Rozga J, Umehara Y, Trofimenko A et al: A Novel Plasma Filtration Therapy for Hepatic Failure: Preclinical Studies. Ther Apher Dial, 2006; 10: 138-44
81. Rozga J: Selective Plasma Filtration Therapy (SEPET™) for Liver Failure-Early Clinical Experience. European Society for Artificial Organs, Krems, Austria, May 2007
82. Sauer IM, Goetz M, Steffen I et al: In vitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD). Hepatology, 2004; 39: 1408-14
83. Davies N, Proven A, Leckie P et al: The Development and Testing of the UCL Liver Support Device (UCL-ARSENEL): Improvement of Survival in Paracetamol-Induced Acute Liver Failure Pigs. Hepatology, 2010; 52(Suppl.): 1092A
84. Ringe H, Varnholt V, Zimmering M et al: Continuous veno-venous single-pass albumin hemodiafiltration in children with acute liver failure. Pediatr Crit Care Med, 2011; 12: 257-64
85. Wilmer A: Detoxifying Capacity and Kinetics of Prometheus® -A New Extracorporeal System for the Treatment of Liver Failure. Blood Purif, 2005; 23: 349-58
86. Mitzner SR, Stange J, Klammt S et al: Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl, 2000; 6: 277-86
87. Sen S, Davies NA, Mookerjee RP et al: Pathophysiological effects of albumin dialysis in acuteon-chronic liver failure: a randomized controlled study. Liver Transpl, 2004; 10: 1109-19
88. Hassanein TI, Tofteng F, Brown RS Jr et al: Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology, 2007; 46: 1853-62
89. Rademacher S, Oppert M, Jórrse A: Artificial Extracorporeal Liver Support Therapy in Patients With Severe Liver Failure: Therapeutic Efficacy of Artificial Extracorporeal Liver Support Therapy. Expert Rev Gastroenterol Hepatol, 2011; 5: 455-63
90. Rifai K, Manns MP: Clinical Experience With Prometheus. Ther Apher Dial, 2006; 10: 132-37
91. Karvellas CJ, Gibney N, Kutsogiannis D et al: Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure. Crit Care, 2007; 11: 215-21
92. Oettl K, Stadlbauer V, Krisper P, Stauber RE: Effect of extracorporeal liver support by molecular adsorbents recirculating system and Prometheus on redox state of albumin in acute-onchronic liver failure. Ther Apher Dial, 2009; 13: 431-36
93. Vaid A, Chweich H, Balk EM, Jaber BL: Molecular adsorbent recirculating system as artificial therapy for liver failure: a meta-analysis. ASAIO J, 2012; 58: 51-59
94. Bañares R, Nevens F, Larsen FS et al., as Relief Study Group: Extracorporeal liver support with the molecular adsorbent recirculating system (MARS) in patients with acute-on-chronic liver failure (AOCLF). The RELIEF Trial. J Hepatol, 2010; 52: S459-60
95. Kribben A, Gerken G, Haag S et al: Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology, 2012; 142: 782-89
96. Anraku M, Yamasaki K, Maruyama T et al: Effect of oxidative stress on the structure and function of human serum albumin. Pharm Res, 2001; 18: 632-39
97. Oettl K, Stauber RE: Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol, 2007; 151: 580-90
98. Jalan R, Schnurr K, Mookerjee RP et al: Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology, 2009, 50: 555-64
99. Chen T-A, Tsao Y-C, Chen A et al: Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol, 2009; 44: 619-25
100. Quinlan GJ, Martin GS, Evans TW: Albumin: biochemical properties and therapeutic potential. Hepatology, 2005; 41: 1211-19